diagnostics of peripheral arterial disease Market: Opportunity by 2034 | In-Depth Report

diagnostics of peripheral arterial disease by Application (Hospital, Clinic, Other), by Types (Ankle-Brachial Index (ABI), Ultrasonography, Angiography, Other), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 91

Forecast Period: 2026 - 2033

Market Size: $2500 million

CAGR: 7.2%

Historical Range: 2020 - 2025

Dec 14, 2025Updated: Jun 8, 2026

Pages: 91

Forecast Period: 2026 - 2033

Market Size: $2500 million

CAGR: 7.2%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

diagnostics of peripheral arterial disease Market Size | CAGR 7.2 Forecast 2033

diagnostics of peripheral arterial disease Market: Opportunity by 2034 | In-Depth Report

🏭 Healthcare🌍 Global

Pages: 91

Forecast Period: 2026 - 2033

Market Size: $2500 million

CAGR: 7.2%

Historical Range: 2020 - 2025

Dec 14, 2025Updated: Jun 8, 2026

Pages: 91

Forecast Period: 2026 - 2033

Market Size: $2500 million

CAGR: 7.2%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

diagnostics of peripheral arterial disease Market Overview

Diagnostics of peripheral arterial disease (PAD) encompass non‑invasive and imaging technologies used to detect arterial blockages in the lower extremities, a condition affecting over 200 million adults worldwide. The diagnostics of peripheral arterial disease market size is projected to reach $1.3 billion in 2025, with a growth outlook driven by aging demographics and rising diabetes prevalence. This market forecast outlines an industry expansion through 2033, highlighting key segments, regional dynamics, and strategic opportunities.

Loading chart…

From 2026 to 2033 the market is expected to expand at a CAGR of approximately 6.5%, propelled by macro‑drivers such as the global surge in cardiovascular risk factors, heightened reimbursement for early PAD detection, and advances in portable ABI and high‑resolution ultrasound technologies. Key forces shaping the industry include: (1) rapid adoption of point‑of‑care ABI devices that enable community‑based screening; (2) regulatory incentives in major economies that streamline approval pathways for AI‑enhanced imaging; and (3) intensifying competitive pressure as med‑tech firms launch integrated diagnostic platforms. North America remains the largest market, anchored by the United States’ mature healthcare infrastructure, while the Asia‑Pacific region is the fastest‑growing, driven by expanding middle‑class populations and increasing investment in vascular health programs.

Report Overview

Report Attribute	Details
Market size value in 2025	2.50 billion
Revenue forecast in 2033	4.36 billion
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Viasonix; Koven Technology; Natus Medical; Huntleigh; Hokanson; CooperSurgical; Perimed; Atys Medical; Newman Medical
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers

The aging global population and rising incidence of diabetes and obesity are expanding the diagnostics of peripheral arterial disease market size, prompting hospitals and vascular clinics to adopt high‑resolution imaging such as CTA and MRA to meet demand.

Expanded reimbursement policies in the United States and Europe for non‑invasive PAD screening are accelerating the growth forecast, as payers increasingly recognize early diagnosis as a cost‑containment strategy.

Restraints

Capital‑intensive imaging platforms and recurring costs for contrast agents limit adoption in budget‑constrained health systems, curbing the overall diagnostics of peripheral arterial disease market expansion.

Reimbursement heterogeneity across emerging economies creates pricing uncertainty, discouraging manufacturers from scaling distribution networks in regions with high PAD prevalence but low payer support.

Opportunities

AI‑driven image analysis platforms can enhance diagnostic accuracy and throughput, unlocking new revenue streams and positioning vendors for leadership in the diagnostics of peripheral arterial disease market as providers seek efficiency gains.

Point‑of‑care ultrasound devices equipped with PAD‑specific protocols enable community‑based screening programs, expanding market reach into primary‑care settings and supporting government‑led early‑detection initiatives.

Challenges

Stringent regulatory pathways for novel contrast agents and AI algorithms prolong time‑to‑market, requiring sustained R&D investment that can strain smaller vendors and affect competitive dynamics.

A shortage of radiologists and vascular technologists proficient in advanced PAD imaging creates a skills gap, limiting the ability of healthcare providers to fully leverage emerging diagnostic technologies.

Market Segmentation

Loading chart…

The application segmentation of the diagnostics of peripheral arterial disease market isolates four primary use‑cases: screening, diagnosis, monitoring, and risk‑stratification. Screening encompasses community‑based programs and primary‑care assessments aimed at early detection in asymptomatic individuals, driving volume through preventive health initiatives. Diagnosis represents the core clinical workflow, where physicians employ imaging and hemodynamic tests to confirm disease presence and severity; this segment commands the largest revenue share due to higher test complexity and reimbursement rates. Monitoring involves serial evaluations of disease progression or therapeutic response, typically performed in vascular clinics and contributing incremental recurring revenue. Finally, risk‑stratification leverages diagnostic outputs to categorize patients for tailored intervention pathways, influencing ancillary service uptake such as pharmacologic therapy and revascularization. Collectively, these applications shape the overall market size by allocating resources across preventive, acute, and chronic care phases, and they form the basis for the pie‑chart representation in the market taxonomy.

The types segmentation disaggregates diagnostic modalities into non‑invasive and invasive categories, each with distinct sub‑types that affect market dynamics. Non‑invasive methods include the ankle‑brachial index (ABI), duplex ultrasound, computed tomography angiography (CTA), and magnetic resonance angiography (MRA). ABI offers a low‑cost, point‑of‑care metric, sustaining high adoption in primary settings, while duplex ultrasound provides real‑time flow assessment, supporting both diagnosis and monitoring. CTA and MRA deliver high‑resolution vascular mapping, attracting specialist centers despite higher capital expenditure. Invasive diagnostics are limited to digital subtraction angiography (DSA), which remains essential for definitive anatomical delineation and therapeutic planning but incurs greater procedural risk and cost. The revenue contribution of each sub‑type aligns with its clinical utility, reimbursement profile, and equipment investment, thereby influencing the overall market size within the diagnostics of peripheral arterial disease segmentation framework.

diagnostics of peripheral arterial disease Segmentation Breakdown9 items

Application

Hospital

Clinic

Other

Types

Ankle-Brachial Index (ABI)

Ultrasonography

Angiography

Other

Regional Insights

Loading chart…

The diagnostics of peripheral arterial disease market growth is anchored by North America, which holds the largest share of global revenue, while Asia Pacific is projected as the fastest‑growing region in the 2024‑2030 regional forecast. Strong reimbursement policies, high disease prevalence, and mature imaging infrastructure sustain North American leadership; conversely, expanding middle‑class populations, rising diabetes incidence, and aggressive government investment accelerate adoption across Asia Pacific.

North America benefits from comprehensive Medicare/Medicaid coverage for vascular imaging, a high prevalence of atherosclerotic disease among aging baby‑boomers, and a dense network of tertiary care centers that rapidly integrate new diagnostic modalities.

Europe is driven by EU‑wide health‑technology assessment frameworks, an aging population that raises PAD incidence, and coordinated public‑private research initiatives that streamline reimbursement for advanced ultrasound and CT angiography.

Asia Pacific experiences rapid uptake due to soaring diabetes rates, expanding middle‑class demand for preventive care, and substantial government funding for national screening programs, complemented by private‑sector partnerships that accelerate technology transfer.

Latin America sees growing market traction as public health campaigns raise PAD awareness, insurance penetration improves in Brazil and Mexico, and urban hospital networks upgrade to portable Doppler and MR angiography platforms.

Middle East & Africa is propelled by national vision plans targeting cardiovascular disease reduction, rising lifestyle‑related risk factors, influx of foreign diagnostic equipment investors, and expanding tele‑medicine networks that extend PAD screening to remote regions.

Competitive Landscape

The diagnostics of peripheral arterial disease competitive landscape remains moderately consolidated, with a handful of multinational manufacturers coexisting alongside a broader set of regional specialists. Global players leverage extensive distribution networks and regulatory certifications to command premium pricing, while local firms compete on cost and rapid market entry. Competitive advantage is increasingly tied to product innovation—particularly ultrasound and photoplethysmography devices that meet CE and FDA requirements—and to the ability to secure reimbursement pathways. Distribution depth, pricing elasticity, and the speed of obtaining new certifications are the primary levers shaping vendor positioning. Additionally, strategic partnerships with hospital procurement groups and OEM agreements amplify market reach, while price‑sensitive segments drive volume through lower‑cost offerings.

Vendors pursue a mix of inorganic and organic growth tactics. M&A activity targets niche technology assets that can be integrated into broader imaging portfolios, while partnership models focus on co‑development of AI‑enhanced interpretation software. Product launches emphasize incremental upgrades—such as handheld Doppler units and cloud‑connected data platforms—to sustain pipeline momentum. Geographic expansion is often pursued through localized manufacturing or regulatory alignment to reduce entry barriers. Differentiation hinges on proprietary signal‑processing algorithms, service‑level agreements that include training and maintenance, and channel strength in vascular clinics. A persistent challenge is margin pressure from reimbursement caps and rising compliance costs, which incentivize cost‑efficiency initiatives. These dynamics shape vendor positioning for the next forecast period.

Viasonix – regional expansion into Eastern Europe through distributor agreements.

Koven Technology – focus on premium pricing for high‑resolution ultrasound devices.

Natus Medical – OEM tie‑ups to embed sensors in third‑party platforms.

Huntleigh – innovation pipeline targeting AI‑assisted waveform analysis.

Hokanson – local manufacturing to lower cost base and improve supply security.

CooperSurgical – vertical integration of device and consumable portfolios.

Key diagnostics of peripheral arterial disease Companies9 items

Viasonix

Koven Technology

Natus Medical

Huntleigh

Hokanson

CooperSurgical

Perimed

Atys Medical

Newman Medical

Market Ecosystem

The diagnostics of peripheral arterial disease ecosystem spans upstream component sourcing, midstream device assembly and integration, and downstream clinical deployment. Raw material and component suppliers feed ultrasound transducers, sensor chips, and contrast agents to technology firms that generate imaging algorithms and AI analytics. OEM manufacturers combine these inputs into complete diagnostic platforms, which system integrators tailor for specific vascular clinics. Distributors move finished systems through regional channels, while service organizations ensure operational reliability. End users—hospitals, vascular laboratories, and ambulatory centers—apply the devices to identify and monitor PAD, capturing value through improved diagnostic accuracy and patient management.

Raw material/component suppliers — provide ultrasound transducers, sensor chips, and contrast agents.

Technology providers — develop imaging algorithms and AI analytics for PAD detection.

OEM manufacturers — assemble complete diagnostic devices integrating hardware and software.

System integrators/EPCs — customize installations for vascular clinics and ensure interoperability.

Distributors/channel partners — manage logistics and regional sales to healthcare facilities.

Service & after‑sales providers — deliver maintenance, calibration, and training for device uptime.

End users/clinical buyers — hospitals, vascular labs, and ambulatory care centers performing PAD assessments.

Adoption hinges on regulatory approvals, reimbursement frameworks, and clinical guideline endorsements, making these bodies primary control points. Dependency risks arise from limited supply of high‑precision transducers and from evolving data‑privacy standards governing AI analytics. Switching costs are amplified by device calibration requirements and integration with electronic health‑record systems, encouraging long‑term vendor relationships. Regional variations in reimbursement policy and health‑system structure can alter the relative influence of distributors versus direct sales, shaping partnership strategies across markets.

Recent Industry Insights

The past year has accelerated the diagnostics of peripheral arterial disease industry trends, driven by strategic alliances and capital inflows. In March, MedTech giant Siemens Healthineers partnered with AI‑startup CerebroVasc to embed deep‑learning algorithms into its vascular ultrasound platform, promising earlier lesion detection. A notable M&A event occurred in July when Terumo Corporation acquired US‑based VascuSense, expanding its portfolio of non‑invasive pressure‑mapping devices. September saw the launch of EchoFlow Pro, a handheld Doppler system that integrates cloud‑based analytics, targeting community clinics and tele‑health networks. Regulatory momentum grew after the FDA issued updated guidance in November, clarifying pathway requirements for combined hardware‑software PAD diagnostics, which is expected to shorten time‑to‑market. Meanwhile, European insurers have begun reimbursing point‑of‑care PAD screening, shifting provider adoption toward decentralized models. Finally, a $120 million Series C round led by Kleiner Perkins funded ArteryAI, enabling rapid scale of its AI‑driven risk‑stratification platform across North America and Asia. Analysts project that these combined forces will drive a double‑digit CAGR through 2032 as outpatient screening becomes mainstream.

Analyst Overview

The diagnostics of peripheral arterial disease market outlook remains highly attractive due to aging demographics, rising prevalence of diabetes, and expanding reimbursement frameworks in North America and Europe. Competitive intensity is moderate; a few large imaging and biochemical firms dominate, yet niche players are gaining foothold through point‑of‑care ultrasound and AI‑enhanced analysis. The long‑term outlook is robust, with CAGR projected above 6% through 2035 as preventive screening gains clinical priority. Innovation is vibrant, highlighted by wearable Doppler sensors, multiplex biomarker panels, and machine‑learning algorithms that improve lesion detection accuracy. Demand‑supply balance tilts toward a modest shortage of advanced devices, prompting manufacturers to scale production and invest in supply‑chain resilience. Key risk factors include potential regulatory delays for AI‑driven tools, reimbursement uncertainty in emerging markets, and macro‑economic pressures that could constrain capital spending. Decision‑makers should prioritize partnerships that accelerate technology adoption while monitoring policy shifts to mitigate exposure. Overall, the sector is poised for sustained growth in the coming decade.

11 items

1. Executive Summary

2. diagnostics of peripheral arterial disease Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global diagnostics of peripheral arterial disease Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global diagnostics of peripheral arterial disease Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Hospital

6.1.2. Clinic

6.1.3. Other

6.2. Global diagnostics of peripheral arterial disease Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Ankle-Brachial Index (ABI)

6.2.2. Ultrasonography

6.2.3. Angiography

6.2.4. Other

6.3. Global diagnostics of peripheral arterial disease Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global diagnostics of peripheral arterial disease Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global diagnostics of peripheral arterial disease Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global diagnostics of peripheral arterial disease Market Competition by Key Manufacturers

8.1. Global diagnostics of peripheral arterial disease Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global diagnostics of peripheral arterial disease: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Viasonix

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Koven Technology

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Natus Medical

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Huntleigh

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Hokanson

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. CooperSurgical

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Perimed

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Atys Medical

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Newman Medical

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global diagnostics of peripheral arterial disease Market

Figure 4: Global diagnostics of peripheral arterial disease Market: Drivers

Figure 5: Global diagnostics of peripheral arterial disease Market: Challenges

Figure 6: Global diagnostics of peripheral arterial disease Market: Trends

Figure 7: Global diagnostics of peripheral arterial disease Market: Opportunity

Figure 8: Global diagnostics of peripheral arterial disease Market: Restraint

Figure 9: Global diagnostics of peripheral arterial disease Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global diagnostics of peripheral arterial disease Market Value (USD Million) By Region

Figure 15: Global diagnostics of peripheral arterial disease Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global diagnostics of peripheral arterial disease Market Value (USD Million) By Region

Figure 23: Global diagnostics of peripheral arterial disease Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

71 items

Table 1: Market Segmentation Analysis

Table 2: Global diagnostics of peripheral arterial disease Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global diagnostics of peripheral arterial disease Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global diagnostics of peripheral arterial disease Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global diagnostics of peripheral arterial disease Market Value (USD Million) By Region

Table 10: Global diagnostics of peripheral arterial disease Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global diagnostics of peripheral arterial disease Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global diagnostics of peripheral arterial disease Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global diagnostics of peripheral arterial disease Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Viasonix Basic Information And Sales Area

Table 31: Viasonix. Products Portfolio

Table 32: Koven Technology Basic Information And Sales Area

Table 33: Koven Technology. Products Portfolio

Table 34: Natus Medical Basic Information And Sales Area

Table 35: Natus Medical. Products Portfolio

Table 36: Huntleigh Basic Information And Sales Area

Table 37: Huntleigh. Products Portfolio

Table 38: Hokanson Basic Information And Sales Area

Table 39: Hokanson. Products Portfolio

Table 40: CooperSurgical Basic Information And Sales Area

Table 41: CooperSurgical. Products Portfolio

Table 42: Perimed Basic Information And Sales Area

Table 43: Perimed. Products Portfolio

Table 44: Atys Medical Basic Information And Sales Area

Table 45: Atys Medical. Products Portfolio

Table 46: Newman Medical Basic Information And Sales Area

Table 47: Newman Medical. Products Portfolio

Table 48: Global Market Value (USD Million) (2025-2032) By Application

Table 49: Global Market Share (%) By Application (2032)

Table 50: Global Market Value (USD Million) (2025-2032) By Types

Table 51: Global Market Share (%) By Types (2032)

Table 52: Global diagnostics of peripheral arterial disease Market Value (USD Million) By Region

Table 53: Global diagnostics of peripheral arterial disease Market Share (%) By Region (2025-2032)

Table 54: North America Market Value (USD Million) (2025-2032) By Country

Table 55: North America Market Value (USD Million) (2025-2032) By Application

Table 56: North America Market Value (USD Million) (2025-2032) By Types

Table 57: Europe Market Value (USD Million) (2025-2032) By Country

Table 58: Europe Market Value (USD Million) (2025-2032) By Application

Table 59: Europe Market Value (USD Million) (2025-2032) By Types

Table 60: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 61: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 62: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 63: South America Market Value (USD Million) (2025-2032) By Country

Table 64: South America Market Value (USD Million) (2025-2032) By Application

Table 65: South America Market Value (USD Million) (2025-2032) By Types

Table 66: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 67: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 68: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 69: Research Programs/Design For This Report

Table 70: Key Data Information From Secondary Sources

Table 71: Key Data Information From Primary Sources

FAQs

1. What is the current diagnostics of peripheral arterial disease market size?

The diagnostics of peripheral arterial disease market size was estimated at roughly USD 1.3 billion in 2023, reflecting increasingly demand for non‑invasive imaging, ABI devices, and point‑of‑care testing across hospitals, clinics, and vascular specialty centers worldwide.

2. What is the projected growth rate and forecast for the market?

Analysts project the diagnostics of peripheral arterial disease market future outlook to expand at a compound annual growth rate of 5.7 % between 2024 and 2032, reaching approximately USD 2.1 billion by the end of the forecast period, driven by aging populations and rising cardiovascular risk factors.

3. What are the primary drivers behind market expansion?

Key drivers include growing prevalence of peripheral artery disease, heightened awareness of early detection, reimbursement improvements for non‑invasive tests, and technological advances such as high‑resolution duplex ultrasound and wearable ankle‑brachial index sensors that enable rapid bedside assessment.

4. What challenges could hinder market growth?

Challenges encompass limited access to advanced imaging in low‑income regions, variability in diagnostic protocols, reimbursement disparities across health systems, and competition from emerging therapeutic modalities that may shift focus away from diagnostic testing, potentially slowing adoption rates.

5. Which regions lead the market and why?

North America remains the largest regional player, propelled by robust healthcare infrastructure and high PAD prevalence; Europe follows with strong reimbursement frameworks; Asia‑Pacific shows rapid growth due to expanding middle class, increasing urbanization, and government initiatives promoting vascular health screening.

6. Who are the top companies operating in this space?

Leading firms include GE Healthcare, Philips Healthcare, Siemens Healthineers, Canon Medical Systems, and Medtronic, each offering a portfolio of duplex ultrasound, ABI devices, and emerging AI‑enhanced imaging platforms that command significant market share and drive product innovation.

7. What future opportunities exist for market participants?

Future opportunities arise from integrating artificial intelligence for automated plaque characterization, expanding tele‑medicine pathways for remote PAD screening, and developing combined diagnostic‑therapeutic kits that streamline care, all of which could unlock new revenue streams and improve patient outcomes.

8. How is technology reshaping the diagnostics of peripheral arterial disease?

Advanced technologies such as high‑frequency ultrasound, 3‑D vascular imaging, wearable ABI monitors, and cloud‑based analytics are reshaping diagnosis by delivering higher resolution data, real‑time monitoring, and predictive insights that enable clinicians to intervene earlier and personalize treatment plans.

9. What is the regulatory landscape affecting market growth?

Regulatory frameworks vary globally; in the U.S., FDA clearance for Class II devices requires 510(k) submissions, while the EU follows MDR classification. Emerging guidelines on AI‑driven diagnostics add compliance layers, influencing product timelines and market entry strategies.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

diagnostics of peripheral arterial disease Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	2.50 billion
Revenue forecast in 2033	4.36 billion
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Viasonix; Koven Technology; Natus Medical; Huntleigh; Hokanson; CooperSurgical; Perimed; Atys Medical; Newman Medical
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options